7 documents found, page 1 of 1
Urgent request for pretomanid label expansion to align with WHO guidelines and ...
Kuksa, L; Andrejak, C; Haecker, B; Bothamley, G; Calcagno, A; Cirillo, DM; Duarte, R; Fatima, R; Ferlazzo, G; Guglielmetti, L; Günther, G; Hewison, CPretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB or multidrug-resistant TB, “when antibiotics used for the latter form of TB do not work or cause unacceptable side effects.” This restricted use implies...
The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Co...
van Leth, F; Brinkmann, F; Cirillo, DM; Dheda, K; Duarte, R; Guglielmetti, L; Kuksa, L; Lange, C; Mitnick, C; Skrahina, A; Zaman, K; Bothamley, Gn/a
Management of patients with multidrug-resistant tuberculosis
Lange, C; Aarnoutse, RE; Alffenaar, JWC; Bothamley, G; Brinkmann, F; Costa, J; Chesov, D; van Crevel, R; Dedicoat, M; Dominguez, J; Duarte, RThe emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public health and economic growth. Never before in the history of mankind have more patients been affected by MDR-TB than is the case today. The World Health Organization reports that MDR-TB outcomes are poor despite staggeringly high management costs. Moreover, t...
Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries
Guenther, G; Leth, F; Alexandru, S; Altet, N; Avsar, K; Bang, D; Barbuta, R; Bothamley, G; Ciobanu, A; Crudu, V; Danilovits, M; Dedicoat, M; Duarte, RRationale: Multidrug-resistant tuberculosis (MDR-TB) is a major burden to public health in Europe. Reported treatment success rates are around 50% or less, and cure rates are even lower. Objectives: To document the management and treatment outcome in patients with MDR-TB in Europe. Methods: We performed a prospective cohort study, analyzing management and treatment outcomes stratified by incidence of patients w...
Treatment outcomes of MDR-TB and HIV co-infection in Europe
Magis-Escura, C; Günther, G; Lange, C; Alexandru, S; Altet, N; Avsar, K; Bang, D; Barbuta, R; Bothamley, G; Ciobanu, A; Crudu, V; Davilovits, M
Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region su...
Dara, M; Solovic, I; Sotgiu, G; D'Ambrosio, L; Centis, R; Tran, R; Goletti, D; Duarte, R; Aliberti, S; de Benedictis, FM; Bothamley, G; Schaberg, TNo evidence exists on tuberculosis (TB) and latent TB infection (LTBI) management policies among refugees in European countries.A questionnaire investigating screening and management practices among refugees was sent to 38 national TB programme representatives of low and intermediate TB incidence European countries/territories of the WHO European Region.Out of 36 responding countries, 31 (86.1%) reported screen...
Call for urgent actions to ensure access to early diagnosis and care of tubercu...
Dara, M; Solovic, I; Sotgiu, G; D'Ambrosio, L; Centis, R; Goletti, D; Duarte, R; Aliberti, S; de Benedictis, FM; Bothamley, G; Schaberg, T; Abubakar, I